anastrozole / Generic mfg. - LARVOL DELTA

Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. (PubMed, Oncol Rev) - "The approved SERMS, tamoxifen, toremifene and raloxifene, are the gold-standard treatments. The only FDA-approved SERD available for treating ER and hormone-positive breast cancers is fulvestrant, and various generations of AIs, including exemestane, letrozole, and anastrozole, have also received FDA approval. Herein, we review the major FDA-approved SERMs and SERDs for treating ER-positive breast cancer, focusing on their mechanisms of action. We also explore molecular events that contribute to the resistance of these drugs to endocrine therapies and combinational strategies with drugs such as cyclin-dependant kinases 4/6 (CDK4/6) inhibitors in clinical trials to combat endocrine drug resistance."

FDA event • Journal • Review • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER

A Rare Case of Metastasis of Renal Cell Carcinoma to Thyroid Gland presenting as Neck Mass, Four Years After Nephrectomy. (ENDO 2025) - "Her cancer history also included right breast ductal carcinoma in situ (DCIS), diagnosed in 2011, and left breast invasive ductal carcinoma (IDC) in 2019, for which she underwent lumpectomy and currently on anastrozole.The patient had been disease-free post-surgery with routine follow-up, including CT scans and renal ultrasounds, whit no signs of recurrence...This case contributes to understanding RCC metastasis to the thyroid, emphasizing the need for vigilance in follow-up care and highlighting the slow-growing, indolent nature of some RCC metastases, which may affect both diagnosis and treatment.*. .*"

Clinical • Breast Cancer • Endocrine Disorders • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • BRAF • CA9 • MME • NKX2-1 • PAX8

Ovarian Stromal Hyperplasia: A Rare Cause of Hyperandrogenism in a 59-Year-Old Female With Treatment Related Menopause and Normal Imaging Findings (ENDO 2025) - "Her treatment for TNBC involved neoadjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel, anastrozole, and Xeloda which resulted in treatment related menopause...Because of the normal imaging findings, a 3-day dexamethasone suppression test was completed, which resulted in persistently elevated Testosterone levels... We present a rare case of hyperandrogenism that was found to be secondary to OSH and resulted in biochemical resolution after surgical intervention. The diagnosis of OSH is difficult but important to consider when the clinical suspicion is high.*. .*"

Stroma • Alopecia • Breast Cancer • Gynecology • Oncology • Rare Diseases • Solid Tumor • Triple Negative Breast Cancer

Leydig Cell Tumor: A Rare Cause of Hyperandrogenism (ENDO 2025) - "Anastrozole was suspected to be the cause of her hyperandrogenism, so it was replaced with Tamoxifen. Sudden hyperandrogenism in postmenopausal women warrants investigation for hormonally active ovarian tumors. These tumors, though distressing, are curable with surgery. Long-term follow-up is essential to monitor for recurrence or metastasis, even in benign cases.*."

Acromegaly • Alopecia • Breast Cancer • Endocrine Disorders • Gynecology • Oncology • Ovarian Cancer • Polycystic Ovary Syndrome • Solid Tumor

A Case of Anastrozole Induced Hyperandrogenism (ENDO 2025) - "Patient was switched from anastrozole to exemestane by her oncologist and was started on spironolactone for persisting hirsutism and scalp hair thinning. Anastrozole as a cause of hirsutism or hyperandrogenism has not been commonly described and may be considered after exclusion of more serious causes.References: Dias JP, Melvin D, Simonsick EM, Carlson O, Shardell MD, Ferrucci L, Chia CW, Basaria S, Egan JM. Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial."

Clinical • Acne Vulgaris • Alopecia • Breast Cancer • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Solid Tumor • Type 2 Diabetes Mellitus

Single cell analysis enables tracking the evolution of resistance to CDK4/6 inhibitors in ER+ breast cancer (AACR 2025) - "To translate these findings to patients, we examined gene expression data from residual tumors after neoadjuvant treatment with palbociclib and the aromatase inhibitor anastrozole in the NeoPalAna trial and found that these tumors showed a similar enrichment of gene signatures associated with DTPs compared to tumors before treatment. Single-cell RNA-seq analysis in barcoded breast cancer cells revealed genes significantly upregulated in expanding clones that show features of the DTP state. We proposed therapeutic targeting of these genes may reduce survival of drug-tolerant cells and prevent the emergence of drug resistance."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays (AACR 2025) - "Herein we explore whether somatic mutation and copy number data from an established 83 gene targeted sequencing panel can improve risk stratification based on clinical factors and GEA alone. Targeted gene-sequencing (TGS) was undertaken in the Anastrozole (A) or Tamoxifen (T) alone or Combined (C) (ATAC) adjuvant trial for estrogen receptor-positive (ER+) breast cancer to identify mutations and copy number variants that are prognostic variables independent of clinical factors and GEA-based risk assessments. Copy number variation (CNV) analysis identified three high-risk deletion events (MAGI3, MET, RB1CC1) in ER+ HER2- breast cancer that predicted worse clinical course than predicted by diagnostic-grade gene expression assays. Thus, the incorporation of CNV-detection into prognostic algorithms has the potential to reduce under-treatment due to low/intermediate-risk mis-assignment. These data are proof-of-concept that prognostication in ER+ HER2- disease can be improved..."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ARID1A • CAV1 • ER • HER-2 • JAK1 • RB1CC1

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (clinicaltrials.gov) - P=N/A | N=1046 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Trial completion date: Jan 2025 ➔ Dec 2026

Trial completion date • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Diseases • Oncology • Solid Tumor • PGR

Endocrine Treatment (Omission or Medication) (GBCC 2025) - "Endocrine Therapy: Advantages and Disadvantages Endocrine therapy, primarily using tamoxifen and anastrozole, reduces the risk of recurrence in ER-positive DCIS. While it reduces recurrence risk, it does not impact survival rates and is associated with significant side effects. Future research should focus on personalized treatment approaches to optimize outcomes while minimizing overtreatment."

Breast Cancer • Cardiovascular • Endometrial Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Diseases • Oncology • Solid Tumor • ER • HER-2

PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) - P1 | N=193 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: May 2025 ➔ Dec 2025

Monotherapy • Trial completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PIK3CA

Drug-Induced Liver Injury Secondary to Endocrine Therapy With Aromatase Inhibitors: A Case Report. (PubMed, Cureus) - "The patient's liver enzymes normalized two months off of the medication, and she decided to proceed with routine observation rather than initiating new endocrine therapy. This case emphasizes the importance of recognizing drug-induced liver injury (DILI) as a rare and serious complication of anastrozole use and highlights the need for consideration of possible risks with endocrine therapies."

Journal • Anorexia • Breast Cancer • Dyslipidemia • Endocrine Disorders • Estrogen Receptor Positive Breast Cancer • Hepatology • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Liver Failure • Metabolic Disorders • Oncology • Solid Tumor • ER

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - P1 | N=198 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • CDK4 • CDK6 • HER-2

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=397 | Active, not recruiting | Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Sep 2030 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Carcinoma erysipeloides secondary to male breast cancer in a patient with BRCA1 and BRCA2 mutations: a clinical presentation and management. (PubMed, BMJ Case Rep) - "Oncology initiated anastrozole and palbociclib treatment, resulting in objective improvement in his breast cancer and his CE. This case highlights a unique presentation of male breast cancer with CE in the context of BRCA mutations and underscores the importance of genetic evaluation and tailored treatment in men with familial breast cancer syndromes."

Journal • Breast Cancer • Dermatology • Genetic Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Lymphoma • Male Breast Cancer • Oncology • Skin Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • HER-2 • PGR

Exploring the relationship between the gut microbiome and musculoskeletal symptoms in breast cancer survivors receiving aromatase inhibitors (ONS 2025) - "Seventy percent were prescribed anastrozole, 12% exemestane, and 14% letrozole. Our results suggest that GM composition is linked to AIMSS and may serve as a potential biomarker, and the symptom could be targeted through dietary manipulation. Larger prospective studies are needed to assess how AIs impact GM over time and its relationship with AIMSS."

Breast Cancer • Oncology • Solid Tumor

Prevention of bicalutamide-induced breast events in patients with prostate cancer: a meta-analysis of randomized controlled trials. (PubMed, J Endocrinol Invest) - "Tamoxifen appears to be the most effective strategy for preventing bicalutamide-induced breast events, with radiotherapy serving as a viable alternative, and anastrozole offering no benefit. Further large-scale, high-quality studies are needed to confirm these findings and refine preventive treatment recommendations."

Journal • Retrospective data • Genito-urinary Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor

ELEGANCE: Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia (clinicaltrials.gov) - P=N/A | N=2883 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

New trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor

Diosmetin Attenuates Painful Symptoms Caused by Antineoplastics Paclitaxel and Anastrozole in Mice. (PubMed, Mol Neurobiol) - "In addition, we observed that anastrozole exacerbated the mechanical allodynia induced by paclitaxel, an effect that was also reversed by diosmetin. These results suggest that diosmetin may be an effective therapeutic alternative for the treatment of painful symptoms caused by antineoplastic drugs, such as paclitaxel and anastrozole."

Journal • Preclinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Oncology • Pain • Peripheral Neuropathic Pain • Solid Tumor

Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer (MBCC 2025) - "Materials and Methods In NATALEE, patients were randomized 1:1 to receive ribociclib (400 mg/day, 3 weeks on/1 week off for 3 years) plus an NSAI (anastrozole 1 mg/day or letrozole 2.5 mg/day for 5 years) or NSAI, with men and premenopausal women receiving goserelin. The DDFS benefit was sustained after the 3-year ribociclib treatment duration, with increasing absolute benefit up to 4 years. These findings further support adding ribociclib to adjuvant NSAI in a broad population of patients with HR+/HER2− EBC."

Clinical • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Skin Cancer • HER-2

A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician's Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/ HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B) (MBCC 2025) - P3 | "Participants will be randomized 2:2:1 to receive saruparib plus camizestrant, physician's choice CDK4/6i (abemaciclib, ribociclib, or palbociclib) plus physician's choice ET (fulvestrant, letrozole, anastrozole, or exemestane), or physician's choice CDK4/6i plus camizestrant, respectively. Status Participant enrollment is ongoing across 185 trial locations in 20 countries. Approximately 500 participants will be randomized across the 3 arms."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • CDK4 • HER-2 • HRD • PALB2

ALISertib in Combination With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Recurrent or Metastatic Breast Cancer: the Phase 2 ALISCA-Breast1 Study (MBCC 2025) - P2 | "Eligible patients will be randomized 1:1:1 to alisertib 30 mg, 40 mg, or 50 mg orally twice daily on days 1 to 3, 8 to 10, and 15 to 17 every 28 days and combined with physician's choice of anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen not previously used in the recurrent or metastatic setting or progressed upon in the adjuvant setting. Tumor tissue will be centrally assessed for biomarkers, including but not limited to RB1, MYC, TP53, ESR1, PI3K/AKT pathway, HER2, and AURKA genomic alterations and/or expression levels. The study is expected to determine the optimal alisertib dose to combine with ET and may identify biomarker(s) that define patients deriving the greatest benefit from alisertib-containing therapy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Infectious Disease • Leukopenia • Neutropenia • Oncology • Solid Tumor • ER • HER-2 • MYC • RB1

Predictors of Clomiphene Citrate Response in the Treatment of Men with Testosterone Deficiency (AUA 2025) - "Multivariable logistic regression was used to identify predictors of treatment success including age, comorbidities, smoking status, baseline TT and LH, concurrent anastrozole, prior androgen deprivation, prior chemotherapy, prior radiation, and prior radical prostatectomy. In men with TD, lower LH levels and higher TT levels were a predictors of CC response. Clinicians can incorporate this into their treatment discussions with patients with TD."

Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) - P1 | N=396 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2

ONE YEAR TREATMENT WITH ANASTROZOLE INCREASES PREDICTED ADULT HEIGHT IN PERI-PUBERTAL BOYS WITH AGGRECAN DEFICIENCY (ESPE-ESE 2025) - No abstract available

Clinical • ACAN

Treatment with Anastrozole Alone or with GH increases Final Height in Pubertal Boys with Short Predicted Adult Height- Real-World Data (ESPE-ESE 2025) - No abstract available

Clinical • Real-world • Real-world evidence